Published online Jun 26, 2021. doi: 10.4252/wjsc.v13.i6.645
Peer-review started: February 5, 2021
First decision: March 17, 2021
Revised: March 29, 2021
Accepted: June 4, 2021
Article in press: June 4, 2021
Published online: June 26, 2021
Processing time: 140 Days and 15.2 Hours
Osteoarthritis is the main cause of economic loss in equine industry as its prompt lameness and limits or ends the equine athletic career. Fewer studies involve comparison tests of mesenchymal stem cells (MSCs) for the chondrogenic lineage in order to find a consistent and long-term therapeutic solution.
Nanoparticle’s technology applied in tridimensional cell culture was an innovative method, as it had not yet been studied in MSCs for chondrocyte differentiation.
To study the three sources of MSCs in order to find out which niche has the best commitment with the cartilage lineage, to use them in joint diseases in the future.
We investigate the chondrogenic differentiation in vitro with tridimensional technology with cell exposure to the nanoparticles, evaluate and quantified the aggrecan, the main proteoglycan present in the hyaline cartilage, and identified aggrecan and keratan sulfate.
Cell culture from the three sources exhibited expression of MSC markers and, after chondrocytes differentiation, demonstrated aggrecan and keratan sulfate.
MSCs derived from synovial fluid and adipose tissue cultured under three-dimensional technology system conditions demonstrated better biocompatibility, suggesting chondrogenic superiority.
Future tests involve clinical application of MSCs in equine diseases and, in vitro and in vivo test based on the development of biomaterial in conjunction with the MSCs of synovial fluid for the evaluation of in vitro efficacy and in vivo safety.